Bloomberg
Centene CEO Doubts Medicare-for-All Will Happen
Dec.18 -- Michael Neidorff, Centene Corp. chief executive officer, says the company will stick to its business strategy and expresses confidence it will prevail during the Covid-19 pandemic. He speaks on "Bloomberg Markets: The Close."
Bloomberg
Health-Care M&A Takes Center Stage With Mylan-Pfizer, Exact-Genomic Deals
Jul.29 -- Bloomberg's Nabila Ahmed takes a look at the latest M&A activity in the health-care industry. She speaks on "Bloomberg Markets: The Close." (Video extended to include full segment.)
Bloomberg
AdvisorShares MD Sees Pot, Alcohol Companies Combining
Dec.27 -- Dan Ahrens, AdvisorShares Investments managing director, says he expects increased M&A activity between marijuana, tobacco and alcohol companies. He speaks with Bloomberg's Julie Hyman on "Bloomberg ETF IQ."
Bloomberg
Split Personality: How a Divided Congress May Hit Banks, Tech & Pharma
Nov.05 -- With a divided U.S. Congress, analysts think bank and pharmaceutical stocks could come out relatively unharmed, or even supported, if Democrats cause gridlock with Donald Trump's agenda. But the pain could continue for tech and...
Bloomberg
Qiming's Leung on Investments in China's Biotech Industry
Sep.02 -- Nisa Leung, managing partner at Qiming Venture Partners, discusses her investments in China's biotechnology industry amid the Covid-19 pandemic. She speaks on the sidelines of the HKEX Biotech Summit with Stephen Engle on...
Bloomberg
Novo Holdings on Asia Biotech Opportunities
Sep.03 -- Amit Kakar, Senior Partner and Head of Asia at Novo Holdings Asia, discusses the investment opportunities in Asia's biotech sector. He speaks with Stephen Engle on the sidelines of the HKEX Biotech Summit.
Bloomberg
Treasury Takes Steps to Curb Tax Inversions
Sept. 22 -- The U.S. Treasury Department announced steps that will make it harder for U.S. companies to move their addresses outside the country to reduce their taxes, clamping down on the practice known as inversions. Peter Cook and...
Bloomberg
Market Winners and Losers in a Trump Presidency
Nov. 9 -- Kate Moore, chief equity strategist at BlackRock, examines the potential market winners and losers of a Donald Trump presidency. She speaks on "Bloomberg Daybreak: Americas."
Bloomberg
Julian Robertson: Biotech Stocks Are Cheap
Sept. 27 -- Julian Robertson, Tiger Management's chairman and chief executive officer, comments on biotech stocks during an interview with Bloomberg's Tom Keene and Mike McKee on "Bloomberg Surveillance Primetime."
Bloomberg
Health-Care M&A: 2016 Market Report Card
Aug. 29 -- Susan Huang, head of M&A Americas at Morgan Stanley, examines the 2016 M&A market with a focus on health care and tends in deal-making. She speaks with Bloomberg's Jeff McCracken on "Bloomberg Markets."
Bloomberg
Biotech Companies Go Public at a Blistering Pace
Sep.10 -- Biotechnology companies have been going public at a blistering pace this year, even as private investors are pouring more and more money,into younger and younger startups. Bloomberg's Tatiana Darie has more on "Bloomberg...
Bloomberg
Galapagos Shares Surge on $5.1 Billion Gilead Investment
Jul.15 -- Andre Hoekema, chief business officer at Galapagos, discusses the $5.1 billion investment into the company by Gilead Sciences Inc. He speaks with Bloomberg's Nejra Cehic on "Bloomberg Surveillance."
Bloomberg
Why Humacyte Is Going Public Via SPAC
Feb.17 -- Dr. Laura Niklason, chief executive officer and founder of Humacyte, discusses the biotech company's decision to go public through a merger with Alpha Healthcare Acquisition Corp., a special purpose acquisition company (SPAC)....
Bloomberg
Capital Link CEO on Asia Markets Outlook
Brett McGonegal, Chairman and CEO at Capital Link, discusses his outlook for Asia markets and strategy. He speaks with Shery Ahn and Haidi Stroud-Watts on "Bloomberg Daybreak: Asia".
Bloomberg
Market Momentum Raising Concern for September Swoon
Sept. 24 -- Russ Koesterich, chief investment strategist at BlackRock, and Bill Janeway, senior advisor at Warburg Pincus, discuss the current state of U.S. stock markets with a focus on momentum and volatility. They speak on Bloomberg...
Bloomberg
Trump Drug Price Fight Shouldn't Surprise Biotech: Nisen
Jan.12 -- Comments from President-elect Donald Trump on drug pricing triggered a sharp decline in biotech stocks on Wednesday. Bloomberg Gadfly columnist Max Nisen explains why the industry should not be surprised by Trump's efforts to...
Bloomberg
2016: Biotech’s Tumultuous Year
Dec.30 -- Bloomberg’s Doni Bloomfield discusses his 2017 outlook for the biotech sector on “Bloomberg Markets.â€
Bloomberg
How Repealing Obamacare Will Affect Pharma, Biotech
Jan.18 -- Krensavage Asset Management CEO Michael Krensavage discusses drug prices and investing in health care companies in light of a potential repeal of Obamacare. He speaks with Vonnie Quinn and David Gura on “Bloomberg Markets.â€
Bloomberg
Why Biotech's $20B Merger Monday May Not Be a Home Run
Jan.22 -- Bloomberg Gadfly columnist Max Nisen discusses Celgene's $9 billion buyout of Juno Therapeutics and Sanofi's $11.6 billion deal for Bioverativ on "Bloomberg Markets." (Nisen is a Bloomberg Gadfly columnist. The opinions...
Bloomberg
How Cambridge Became a Biotech Hub
Oct.05 -- Alexandria Real Estate Equities chairman and co-founder Joel Marcus sit down with Bloomberg's Rebecca Spalding in Cambridge, Massachusetts.
Bloomberg
Corteva CEO Sees 'Tremendous' Amount of Demand After DuPont Separation
Jun.03 -- James Collins, Corteva Agriscience chief executive officer, discusses the company's separation from DowDuPont Inc. with Bloomberg's Vonnie Quinn and Ed Hammond on "Bloomberg Markets."
Bloomberg
How Venture Capital is Investing in Gene Therapy
May.13 -- Alexis Borisy, Third Rock Ventures partner, discusses the fund's biotech investment strategy on "Bloomberg Technology."